Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

Clinical trial NCT07324473 · NOT_YET_RECRUITING

Trial details

NCT number

NCT07324473

Sponsor

First Affiliated Hospital of Chongqing Medical University

Status

NOT_YET_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2026-01-01

Primary completion

2028-01-01

Enrollment

65

View on ClinicalTrials.gov